MedicaidPrior AuthMedium impact
Monjuvi® (tafasitamab-cxix) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Oct 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has established a new prior authorization policy for Monjuvi (tafasitamab-cxix), an IV cancer treatment for certain blood cancers. Prior authorization will be required for all Monjuvi treatments starting October 1, 2025, with specific criteria for diffuse large B-cell lymphoma and follicular lymphoma patients.
Action Required
Before October 1, 2025: Billing team must update prior authorization requirements for Monjuvi (tafasitamab-cxix) treatments for Humana Medicaid Indiana patients. Visit www.humana.com/PAL to obtain medical and procedural coding information and establish prior authorization workflow. Oncology providers must document patient eligibility criteria including diagnosis, relapsed/refractory status, transplant eligibility, and combination therapy plans. Claims will be denied without proper prior authorization.